About Kancera
Kancera is a publicly listed company based in Solna (Sweden) founded in 2010. Small molecule therapeutics for cancer are developed pre-clinically. The company has 5 employees. Kancera offers products and services including FRACTAL, KANDOVA, and KAND145. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Kancera AB.
Company details
Kancera was founded in 2010 and is based in Solna, Sweden, within the biotechnology sector. Small molecule drugs targeting cancer are developed through five projects, including ROR inhibitors for solid tumors and leukemia, PFKFB3 inhibitors for solid tumors, HDAC6 inhibitors for myeloma, fractalkine antagonists for tumor growth and pain, and epigenetic inhibitors for parasitic diseases like malaria. Candidates are licensed to larger pharmaceutical firms before clinical trials.
- Headquarters Solna, Sweden
- Employees 5
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website kancera.com
- Social LinkedIn
- Legal Name Kancera Ab
- Net Profit-$4.04 M (USD)31.32as on Dec 31, 2024
- EBITDA-$4.19 M (USD)30.12as on Dec 31, 2024
- Latest Funding Round$307.52K (USD), Grant
Aug 2018
- Investors
- Employee Count5
Products & Services of Kancera
Kancera offers a comprehensive portfolio of products and services, including FRACTAL, KANDOVA, and KAND145.
Fraktalkin-blocking drug for cancer and immune regulation treatments.
Therapy for cardiovascular diseases targeting fraktalkin system.
Preclinical project for inflammation and cancer cell control.
Funding Insights of Kancera
- Total Rounds 2
- Last Round Grant — $307,520
- First Round $590,492
(Sep 2016)
- Investors Count 1
All 2 funding rounds of Kancera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $307,520 | Grant | – | – | |
| Sep 2016 | $590,492 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Kancera
Kancera has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Kancera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Kancera
Kancera is a publicly listed company on the OMXSTO with ticker symbol KAN in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Feb 2011
- Listed onNASDAQ OMX: KAN
- Listed entityKancera AB
- Exchange sectorHealth technology
- Share price0.30 SEK (-2.91% on the day) · 2025-09-23
- Market capitalisation37,446,542.00 SEK
- EPS (diluted, trailing year)-0.33 SEK
- Volume (last session)469,905
- Analyst consensusNeutral
Financials of Kancera
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -44.6M SEK | -46.2M SEK | |
| 2023 | -64.9M SEK | -66.1M SEK | |
| 2022 | -52.5M SEK | -52.3M SEK | |
| 2021 | -45.7M SEK | -46.6M SEK | |
| 2020 | 90,000 SEK | -47.6M SEK | -50.1M SEK |
Detailed financial statements for Kancera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kancera
4 dated milestones of Kancera across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Kancera is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $590K.
- Funding Latest funding round, Grant, of $308K.
Web traffic of Kancera
Websites that share an audience with Kancera (kancera.com).
- Unique visitors1.9K
per month
- Global rank#4,801,729
among all websites
- Category rank#5,653
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.1
- Average visit1 sec
- DevicesDesktop 21% · Mobile 79%
Websites whose visitors overlap most with Kancera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| iatriko.gr | 100% | 260.8K | #183,957 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kancera
Complete news archive for Kancera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kancera
Kancera was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Kancera is headquartered in Solna, Sweden.
Kancera has 5 employees.
Kancera was founded in 2010 and is based in Solna, Sweden, within the biotechnology sector. Small molecule drugs targeting cancer are developed through five projects, including ROR inhibitors for solid tumors and leukemia, PFKFB3 inhibitors for solid tumors, HDAC6 inhibitors for myeloma, fractalkine antagonists for tumor growth and pain, and epigenetic inhibitors for parasitic diseases like malaria. Candidates are licensed to larger pharmaceutical firms before clinical trials.
Kancera offers FRACTAL, KANDOVA, and KAND145.
Yes, Kancera is publicly traded on OMXSTO under the ticker symbol KAN.
Kancera has 1 investor. Key investors include European Union.
Kancera operates through Kancera Ab.